EXPERTS-ALS, the UK's rapid drug-screening platform for MND, has ruled out metformin and nifedipine after an interim analysis, a result researchers say proves the platform is working exactly as design...

One-day conference on emerging themes in ALS/MND research and in the clinic.

New Sheffield research suggests apathy in MND is often about effort, not motivation, recruited through Join MND Research. Read the findings.

EXPERTS-ALS is a UK-wide platform designed to rapidly test potential MND treatments. Meet the first three drugs — metformin, nifedipine, and ropinirole — now open to recruitment.

Discover how the MND Association leads global research to find a cure. Explore our cutting-edge grants and see how we fund the best science to defeat MND.

Raya Therapeutic's smilagenin has been selected for EXPERTS-ALS. Read how this new drug could accelerate the search for MND treatments.

Celebrating three years in MND research: building infrastructure, accelerating trials, and driving progress toward effective treatments.

Our biosampling platform has recruited 212 participants, exceeding its target and advancing biomarker research..

A new systematic review from KCL highlights how biomarkers, such as NfL, are enabling earlier treatment assessments and personalised medicine.

A new study reveals what people with MND need when deciding on genetic testing, including clear information and tailored support.

Findings from the MND Register project will be published here, as well as via a patient newsletter. Results will also be disseminated through scientific publication, conference presentation and patien...

Get involved You can now take part in MND research without having to travel. In collaboration with researchers at the University of Sheffield, we’ve created a secure online platform that makes it s...

Discover how repurposed drugs are helping accelerate the search for effective treatments for MND through innovative UK research.

A new study suggests that MND may slow molecular transport and cell growth before nerve cells die. This could help identify new therapeutic targets.

A new study finds traumatic brain injury linked to a short-term rise in MND risk, suggesting this may reflect early disease signs, not cause them.

Former England captain Lewis Moody says in an exclusive BBC interview he has

One of the most devastating diseases finally has a treatment that can slow its progression and transform lives, tearful doctors tell BBC.

A 1.5-day symposium showcasing current MND research, and a celebration of Euan's legacy, including Euan's Guide and SpeakUnique.

Raya Therapeutic’s ALS/MND compound joins the UK EXPERTS-ALS trial, aiming to accelerate development of a new promising treatment.

A new international challenge prize has been launched to transform drug discovery for ALS, the most common form of MND through AI.

A new study has identified a blood-based protein signature that may predict ALS up to ten years before symptoms appear.

A simple finger-prick blood test could revolutionise how motor neuron disease and other neurological conditions are monitored.

The MHRA has approved the use of tofersen, the first licensed treatment in the UK for MND caused by a variation in the SOD1 gene.

The ambitious £7.2 million Research Nurse Network will give more people diagnosed with motor neurone disease (MND) the opportunity to take part in vital research

Research has found that disrupted sleep may offer some clues to possible early warning signs of the ALS or FTD.

On MND Awareness Day, we’re spotlighting the projects accelerating real progress and explaining why translational research is key.

Read about some of our latest findings from the MND Register that were showcased at the ENCALS Meeting 2025 in Turin, Italy.

International Conference, in partnership with the UK MND Research Institute, on ALS / MND - TRANSLATING TARGETS TO THERAPIES

The new MND Register website helps track MND across the UK and support research into who is affected, how, and why. Visit to learn more.

The primary objective of the MND Register is to build a centralised database of patients with MND across England, Wales and Northern Ireland.

A new study highlights how disrupted energy production in nerve cells is caused by disrupted cell communication, offering a potential new treatment target.

The UK MND Clinical Studies Group has released a statement regarding the MIROCALS clinical trial results, recently published in The Lancet.

Researchers across the country are carrying out world-leading MND research in a coordinated way to accelerate the search for a cure.

A new study has explored how toxic proteins build up in the nervous system and whether future treatments might help stop them.

The international Lighthouse II clinical trial investigating the HIV drug Triumeq as a potential treatment for MND has been halted early.

Discover the cutting-edge research latest breakthroughs we fund to advance the knowledge and treatment of Motor Neurone Disease (MND)

This is "TURNING THE TIDE PART 2" by Quickfire on Vimeo, the home for high quality videos and the people who love them.

Showcasing our pioneering research Last week, MP members of the All-Party Parliamentary Group (APPG) on Motor Neuron Disease (MND) visited King’s College London to witness firsthand the pioneering res...

As neurologists specialising in the care of people living with motor neuron disease, we are receiving increasing enquiries about a drug called ellorarxine. Many of our patients are asking for access, ...

EXPERTS-ALS is a ground-breaking initiative to accelerate the development of new treatments for amyotrophic lateral sclerosis (ALS). We’re excited to showcase one of our flagship projects, the EXPErim...